Table 4.
Base-case outcomes for Model 2
| Outcome | UBT | mFAT |
|---|---|---|
| Economic outcomes per patient, US$ | ||
| Total costs | 336.75 | 326.24 |
| Tests | 88.62 | 9.52 |
| Physician visits | 146.88 | 146.88 |
| Second-line eradication | 20.63 | 22.28 |
| Excess lifetime costs | 80.63 | 147.57 |
| Incremental costs | ||
| Costs per accurately diagnosed case, US$ | 399.91 | 699.08 |
| ICER, US$/QALY gained (UBT vs mFAT) | – | 28.13 |
| UBT cost-effective vs mFAT? | – | Y |
| Health outcomes per patient | ||
| Cases accurately diagnosed as positive (n) | 0.15 | 0.09 |
| Cases accurately diagnosed as negative (n) | 0.69 | 0.38 |
| Reduced QALYs due to continuing H. pylori infection | 0.45 | 0.82 |
Abbreviations: ICER, incremental cost-effectiveness ratio; mFAT, monoclonal fecal antigen test; QALYs, quality-adjusted life-years; UBT, urea breath test; Y, yes; H. pylori, Helicobacter pylori.